retrospect
analysi
conduct
multicent
databas
critic
ill
patient
mer
admit
intens
care
unit
icu
hospit
citi
saudi
arabia
septemb
januari
detail
cohort
report
previous
patient
current
analysi
may
includ
previou
singlecent
studi
patientlevel
inform
consent
requir
institut
review
board
irb
particip
center
approv
studi
particip
center
follow
saudi
arabian
ministri
health
guidelin
mer
diagnost
test
patient
defin
mer
posit
merscov
realtim
revers
transcript
polymeras
chain
reaction
result
rrtpcr
target
amplif
upstream
e
protein
upe
gene
open
read
frame
specimen
obtain
nasopharyng
swab
sputum
nonintub
patient
tracheal
aspir
bronchoalveolar
lavag
intub
patient
patient
test
posit
merscov
followup
respiratori
sampl
collect
discret
treat
team
approxim
time
per
week
infect
control
purpos
current
analysi
exclud
patient
enrol
random
control
trial
rct
mer
antivir
therapi
start
enrol
patient
novemb
merscov
infect
treat
combin
lopinavirritonavir
interferon
miracl
trial
main
exposur
rbvrifn
therapi
defin
use
rbvrifn
combin
rbv
alon
rifn
alon
compar
group
use
neither
rbv
rifn
three
differ
type
rifn
use
current
cohort
pegasi
hoffmannla
roch
co
genentech
south
san
francisco
california
pegintron
merck
sharp
dohm
whitehous
station
new
jersey
rebif
serono
rockland
massachusett
commonli
use
dose
protocol
rbvrifn
patient
mer
particip
hospit
shown
supplementari
tabl
use
standard
case
report
form
document
demograph
clinic
present
underli
comorbid
final
outcom
collect
sequenti
organ
failur
assess
sofa
score
physiolog
laboratori
paramet
icu
day
document
therapeut
intervent
includ
corticosteroid
mechan
ventil
oxygen
rescu
therapi
nitric
oxid
prone
ventil
high
frequenc
oscillatori
ventil
extracorpor
membran
oxygen
pack
red
blood
cell
transfus
vasopressor
therapi
renal
replac
therapi
primari
outcom
mortal
also
assess
time
merscov
rna
clearanc
respiratori
sampl
patient
least
followup
rrtpcr
perform
diagnost
test
clearanc
time
icu
admiss
test
neg
occas
without
posit
test
afterward
assess
rbvrifn
safeti
profil
evalu
serial
level
hemoglobin
white
blood
cell
wbc
count
platelet
count
aspart
aminotransferas
ast
alanin
aminotransferas
alt
bilirubin
intern
normal
ratio
inr
lactic
acid
creatinin
secondari
outcom
icu
hospit
mortal
icu
hospit
length
stay
compar
baselin
characterist
intervent
outcom
patient
receiv
rbvrifn
use
test
fisher
exact
test
categor
variabl
student
test
mannwhitney
u
test
continu
variabl
serial
measur
test
differ
group
time
use
repeatedmeasur
analysi
varianc
bonferroni
correct
multipl
comparison
imput
miss
valu
construct
model
assess
associ
rbvrifn
therapi
mortal
adjust
baselin
characterist
timevari
confound
analyt
model
detail
previou
studi
first
creat
logist
regress
model
adjust
follow
priori
baselin
variabl
clinic
interest
signific
variabl
univari
level
p
variabl
includ
diabet
liver
diseas
renal
diseas
malign
sofa
score
first
day
icu
admiss
sourc
infect
year
juli
appli
proc
genmod
procedur
sa
softwar
second
creat
cox
proport
hazard
model
adjust
covari
account
rbvrifn
therapi
timevari
covari
third
creat
margin
structur
model
analysi
invers
probabl
treatment
weight
account
timevari
confound
like
influenc
decis
initi
rbvrifn
therapi
time
may
associ
mortal
calcul
stabil
weight
probabl
subject
receiv
treatment
censor
day
therapi
icu
discharg
mortal
whichev
came
first
includ
model
select
baselin
characterist
well
timedepend
variabl
sofa
index
day
rbvrifn
initi
previou
day
ventil
statu
index
day
previou
day
ventil
noninvas
ventil
invas
mechan
ventil
oxygen
rescu
therapi
hemoglobin
wbc
count
ast
creatinin
index
day
corticosteroid
therapi
index
day
includ
corticosteroid
therapi
timevari
covari
shown
previous
corticosteroid
therapi
critic
ill
mer
patient
might
prolong
merscov
rna
clearanc
although
associ
differ
mortal
valu
record
day
imput
miss
valu
remain
day
supplementari
method
use
weighttrim
approach
deal
extrem
weight
weight
percentil
valu
fix
percentil
valu
weight
percentil
valu
fix
percentil
valu
process
continu
averag
weight
reach
approxim
use
weight
regress
model
use
weight
take
consider
repeatedmeasur
natur
data
estim
associ
rbvrifn
mortal
carri
sensit
analys
examin
associ
rbv
therapi
alon
compar
rbv
rifn
therapi
alon
compar
rifn
account
possibl
variat
site
carri
sensit
analysi
use
logist
regress
model
adjust
cluster
center
addit
previous
mention
baselin
variabl
evalu
associ
differ
type
rifn
mortal
use
similar
logist
regress
model
adjust
cluster
center
also
creat
model
assess
associ
rbvrifn
therapi
merscov
rna
clearanc
adjust
baselin
characterist
timevari
confound
first
carri
cox
proport
hazard
model
adjust
baselin
covari
mention
earlier
account
rbvrifn
therapi
timevari
covari
censor
patient
never
clear
merscov
rna
time
last
rrtpcr
test
second
creat
margin
structur
cox
proport
hazard
model
incorpor
stabil
weight
estim
effect
rbvrifn
therapi
merscov
rna
clearanc
similar
approach
margin
structur
model
use
mortal
analys
conduct
use
sa
version
softwar
sa
institut
cari
north
carolina
studi
approv
nation
guard
health
affair
irb
irb
particip
site
inform
consent
waiv
irb
retrospect
natur
studi
patient
mer
cohort
patient
exclud
enrol
miracl
trial
remain
cohort
includ
patient
receiv
rbvrifn
therapi
tabl
patient
group
similar
age
sex
bodi
mass
index
sourc
admiss
tabl
comorbid
common
receiv
rbvrifn
vs
p
patient
receiv
rbvrifn
like
diabet
vs
p
chronic
renal
diseas
vs
p
less
like
chronic
liver
diseas
vs
p
note
rbvrifn
recipi
lower
sofa
score
treat
median
vs
p
tabl
icu
stay
provis
mechan
ventil
oxygen
rescu
therapi
renal
replac
therapi
vasopressor
therapi
similar
group
tabl
icu
stay
patient
receiv
rbvrifn
therapi
like
receiv
corticosteroid
therapi
compar
receiv
rbvrifn
vs
p
tabl
crude
mortal
higher
patient
receiv
rbvrifn
therapi
compar
vs
p
tabl
multivari
logist
regress
show
rbvrifn
therapi
associ
increas
mortal
adjust
odd
ratio
aor
confid
interv
ci
p
tabl
use
cox
proport
hazard
analysi
account
timevari
exposur
rbvrifn
therapi
also
associ
increas
mortal
adjust
hazard
ratio
ahr
ci
p
howev
use
margin
structur
model
rbvrifn
therapi
associ
signific
differ
mortal
aor
ci
p
crude
analysi
show
merscov
rna
clearanc
differ
group
median
day
vs
day
p
tabl
use
cox
proport
hazard
regress
model
adjust
baselin
covari
account
rbvrifn
therapi
timevari
covari
signific
associ
rbvrifn
faster
merscov
rna
clearanc
ahr
ci
p
margin
structur
cox
proport
hazard
model
similarli
show
signific
associ
ahr
ci
p
analys
rbv
therapi
vs
rbv
rifn
vs
rifn
consist
result
primari
analysi
signific
associ
mortal
merscov
rna
clearanc
use
margin
structur
model
tabl
logist
regress
model
adjust
cluster
center
addit
previous
mention
baselin
variabl
remain
associ
rbvrifn
mortal
examin
differ
type
rifn
mortal
use
similar
logist
regress
model
adjust
cluster
center
show
similar
result
supplementari
tabl
differ
group
group
time
hemoglobin
wbc
count
platelet
count
ast
alt
bilirubin
inr
lactic
acid
creatinin
supplementari
figur
howev
patient
treat
rbvrifn
receiv
blood
transfus
compar
treat
rbvrifn
vs
p
tabl
benefit
rbvrifn
suggest
preclin
studi
observ
studi
account
baselin
timevari
differ
among
critic
ill
patient
mer
treat
rbvrifn
demonstr
rbvrifn
associ
decreas
mortal
faster
merscov
rna
clearanc
possibl
explan
lack
clinic
virolog
benefit
first
shown
rbv
concentr
requir
inhibit
merscov
replic
much
higher
clinic
achiev
concentr
oral
dose
second
lack
rifn
effect
may
relat
type
use
one
studi
examin
vitro
merscov
suscept
differ
rifn
prepar
rifnunivers
found
strongest
merscov
inhibit
time
lower
previous
report
inhibitori
concentr
uml
anoth
vitro
studi
found
serum
concentr
achiev
therapeut
dose
time
higher
vitro
inhibitori
concentr
merscov
wherea
rifn
prepar
rbv
lower
inhibitori
level
note
none
patient
current
cohort
receiv
rct
miracl
current
recruit
patient
examin
effect
combin
lopinavirritonavir
mortal
hospit
patient
mer
third
posit
modest
effect
observ
previou
rhesu
macaqu
experi
occur
earli
treatment
hour
inocul
merscov
administr
high
dose
contrast
took
median
day
patient
cohort
present
hospit
anoth
day
start
therapi
assess
safeti
profil
rbvrifn
compar
level
hemoglobin
wbc
count
platelet
count
ast
alt
bilirubin
inr
lactat
creatinin
found
differ
group
icu
stay
howev
data
interpret
context
potenti
timevari
confound
note
found
patient
treat
rbvrifn
receiv
blood
transfus
patient
treat
rbvrifn
consist
find
previou
studi
chang
may
relat
hemolysi
induc
rbv
therapi
studi
demonstr
account
timevari
confound
substanti
influenc
result
observ
studi
studi
found
associ
rbvrifn
higher
crude
mortal
crude
analysi
adjust
baselin
characterist
alon
logist
regress
adjust
baselin
characterist
includ
time
initi
rbvrifn
cox
proport
hazard
analysi
ultim
find
evid
rbvrifn
therapi
associ
reduc
mer
mortal
adjust
baselin
timedepend
covari
use
margin
structur
model
find
suggest
much
observ
increas
mortal
may
relat
confound
due
indic
bia
call
caution
interpret
observ
studi
account
timevari
confound
studi
examin
rbvrifn
therapi
larg
multicent
cohort
critic
ill
patient
mer
limit
includ
retrospect
natur
lack
random
therefor
inevit
initi
imbal
potenti
confound
although
margin
structur
model
adjust
timevari
confound
unmeasur
confound
entir
exclud
quantit
data
viral
load
avail
practic
repeat
merscov
rrtpcr
vari
among
center
compet
risk
mortal
suffici
data
assess
merscov
rna
clearanc
avail
patient
rct
remain
best
approach
deriv
unbias
estim
treatment
effect
patient
includ
studi
diagnos
mer
prior
launch
first
therapeut
rct
mention
earlier
miracl
sinc
effort
focus
consid
elig
patient
trial
conclus
rbvrifn
therapi
rbv
andor
associ
reduct
mortal
faster
merscov
rna
clearanc
futur
studi
test
antivir
clinic
effect
newer
antivir
intervent
show
promis
result
relev
anim
model
